DUBLIN, Ohio, June 1, 2017 /PRNewswire/ -- Cardinal Health
Specialty Solutions today introduced 2017 Oncology
Insights, the first in a series of research reports to provide
perspective on key issues for specialty care providers, biopharma
companies and other healthcare stakeholders. The report documents
how oncologists view critical issues impacting their practices,
including the transition to value-based reimbursement, use of
real-world evidence to make treatment decisions and the role of
pharmaceutical companies in providing patient support
services.
"Oncology care has never been more complex, with a variety of
issues creating both challenges and opportunities for those working
to advance cancer care," said Joe
DePinto, president of Cardinal Health Specialty Solutions.
"As a leading provider of solutions to the specialty care industry,
it is our hope that this research helps promote informed
discussions among healthcare stakeholders that lead to better
solutions."
2017 Oncology Insights was released in conjunction with
the 2017 annual meeting of the American Society of Clinical
Oncology (ASCO). The findings are based on three oncology summits
conducted by Specialty Solutions earlier this year. In total, the
summits brought together more than 170 oncologists from across
the United States, including a
diverse mix of community and hospital-based practices, to explore
topics critical to their practices.
Key findings include:
- Oncologists lack confidence that the new reimbursement
models for Medicare patients under the Medicare Access and CHIP
Reauthorization Act (MACRA) will improve quality of care and reduce
costs. Nearly nine out of 10 participating oncologists are not
confident that MACRA will help improve patient outcomes and the
total cost of care in the long run.
- While data from clinical trials remains the primary
information source for making treatment decisions, participating
oncologists indicated a strong interest in real-world evidence
(RWE) and patient-reported outcomes (PRO). For instance, about
three out of four participants agree that RWE is necessary to
inform treatment decisions due to the limitations of clinical
trials.
- Patient support programs should be improved – and
pharmaceutical companies should play a key role. The majority
of participants, more than 86 percent, said pharmaceutical
companies should play a larger role in patient support programs. In
addition, only 8 percent said patient education and
adherence programs offered by manufacturers are "essential,
fairly common, easy to use and effective."
The report also includes viewpoints from three Cardinal Health
Specialty Solutions experts:
Chadi Nabhan, MD, chief medical officer; Jennifer Fillman;
vice president and general manager; and Jonathan Kish, PhD, health
economics and outcomes research director.
Cardinal Health Specialty Solutions plans to issue similar
reports using data from future research summits.
Learn more and request a copy of the Oncology Insights report at
www.cardinalhealth.com/oncologyinsights.
For media: to request an advance copy
of the report, please contact Courtney
Tobin at (614) 553-3539 or Courtney.Tobin@cardinalhealth.com.
About Cardinal Health
Cardinal Health, Inc.
is a global, integrated healthcare services and products company,
providing customized solutions for hospitals, healthcare systems,
pharmacies, ambulatory surgery centers, clinical laboratories and
physician offices worldwide. The company provides clinically proven
medical products and pharmaceuticals and cost-effective solutions
that enhance supply chain efficiency from hospital to home.
Cardinal Health connects patients, providers, payers, pharmacists
and manufacturers for integrated care coordination and better
patient management. As a distributor, Cardinal Health helps ensure
pharmacists, and the consumers they serve, have access to
medications they need while working to help prevent prescription
drug diversion; therefore, along with its education partners,
Cardinal Health created Generation Rx, a national program to help
prevent the misuse of prescription medications. Backed by nearly
100 years of experience, with more than 40,000 employees in nearly
60 countries, Cardinal Health ranks among the top 25 on the
Fortune 500. For more information, visit cardinalhealth.com,
follow @CardinalHealth on Twitter and connect on LinkedIn at
linkedin.com/ company/cardinal-health.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/research-based-insights-on-oncology-published-by-cardinal-health-specialty-solutions-300467053.html
SOURCE Cardinal Health